Niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Correlative measures of tumor response in phase II GALAHAD study.
Matthew R. Smith, Karim Fizazi, Shahneen Sandhu, William Kevin Kelly, Eleni Efstathiou, Primo N. Lara, Evan Y. Yu, Daniel J. George, Kim N., Fred Saad, Jason M. Summa, Jamie Freedman, Gary Mason, Byron M. Espina, Eugene Zhu, Deborah Ricci, Linda A. Snyder, Jason S. Simon, Shinta Cheng, Howard I. Scher (2020). Niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Correlative measures of tumor response in phase II GALAHAD study.. , 38(6_suppl), DOI: https://doi.org/10.1200/jco.2020.38.6_suppl.118.
